Antimicrobial resistance of Vibrio cholerae O1 strains isolated during cholera epidemics in eastern Democratic Republic of Congo between January 2011 and June 2022

Author:

NDEBA Patrick AYONGA1,SHINGA Bruce WEMBULUA2,WONE Fatimata1,BARDIGUYO Alain-Bruno1,DIALLO Lassina1,MPINGA Jackson BYAMUNGU3,KITUTU Henriette MULASI3,SENGA Raphael KABANGWA KAKONGO3,CISSE Viviane Marie-Pierre1,TINE Roger Clément Kouly4

Affiliation:

1. Department of Infectious and Tropical Diseases, National University Hospital Center of Fann, Faculty of Medicine, Pharmacy and Odontology, Cheikh Anta-Diop University, Dakar-Senegal

2. Unit of Infectious and Tropical Diseases, Faculty of Medicine, University of Goma, Goma, North-Kivu, DR Congo

3. Provincial Public Health Reference Laboratory AMI LABO, Goma, North Kivu, DR Congo

4. Department of Medical Biology and Functional Explorations, Faculty of Medicine, Pharmacy and Odonto-Stomatology – fmpos, UCAD, Dakar-Senegal

Abstract

Abstract Background Although the mainstay of cholera treatment remains rehydration, treatment with antibiotics is recommended in serious forms and on specific sites. However, since the late 1970s, resistance to antibiotics in strains of Vibrio cholerae (Vc) has been observed and now threatens the effective treatment and control of cholera. Objective and Methods This cross-sectional, retro-prospective, descriptive and analytical study aims to describe the long-term evolution of the antibiotic resistance profile of Vibrio choleraeO1 strains isolated at the provincial public health laboratory of North Kivu during cholera epidemics in Eastern Democratic Republic of Congo (DRC) from January 1, 2011 to June 30, 2022. Results A total of 4832 isolates of Vibrio cholerae O1 were collected, more than half of them (72.46%, n=3175) in the province of North Kivu. Of the 3 serotypes, Vc O1 Inaba was the majority (57.6%, n=2522). Among the 4382 strains of Vc O1, very high levels of resistance were found to ampicillin (74.7%), nalidixic acid (83.8%), erythromycin (73.6%), chloramphenicol (68.8%) and Sulfamethoxazole/Trimethoprim (82%). A resistance of 30% (1316/4382) was found to doxycycline, a molecule recommended by the WHO as first-line in the treatment of cholera. We found 27 different resistance profiles (MDR) with respect to the 5 main molecules recommended in anticholera therapy. In the analytical study, we observed a statistically significant evolution over time (p=0.000) of these MDR profiles, including 5% in 2011 against nearly 40% between 2021 and 2022; with a distribution statistically dependent on age (p=0.0003) including 57.4% of cases in children under 15 (27% in those under 5); with a predominance (69%) in the province of North Kivu. Conclusion The resistance of Vibrio cholerae 01 to common antibiotics is high in eastern DRC and tends to increase over time. The abusive and inappropriate use of antibiotics is one of the major causes of this emergence of antimicrobial resistance. Close monitoring and measures for the proper use of antibiotics will be necessary to stem this scourge.

Publisher

Research Square Platform LLC

Reference33 articles.

1. Development of a Hexaplex PCR Assay for Rapid Detection of Virulence and Regulatory Genes in Vibrio cholerae and Vibrio mimicus;Singh DV;J Clin Microbiol

2. Harris JB, LaRocque RC, Qadri F, Ryan ET, Calderwood SB.Cholera. Lancet Lond Engl. 2012 Jun30;379(9835):2466–76.

3. Centers for Disease Control and Prevention CDC. Recommendations for the Use of Antibiotics for the Treatment of Cholera. Guidelines for Cholera Treatment with Antibiotics, June 1 2022. Available at URL: https://www.cdc.gov/cholera/treatment/antibiotic-treatment.html#print

4. Aubry P, Gauzère BA. Cholera News 2020. Med. Trop. Bordeaux: Center René Labusquière, Institute of Tropical Medicine, University of Bordeaux; 2020. p. 10.

5. Updated Global Burden of Cholera in Endemic Countries;Ali M;PLoS Negl Too Dis

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3